About Cleavage and polyadenylation specificity factor subunit 3
Cleavage and polyadenylation specificity factor subunit 3 (CPSF3) is a protein
from Homo sapiens identified by UniProt accession
Q9UKF6, 684 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
Disease associations (49)
Diseases linked to this target (Open Targets).
- neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures · score 0.54
- neurodegenerative disease · score 0.53
- neurodevelopmental disorder with hypotonia, microcephaly, and seizures · score 0.42
- complex neurodevelopmental disorder · score 0.37
- body height · score 0.10
- hepatocellular carcinoma · score 0.09
- mean platelet volume · score 0.08
- lung adenocarcinoma · score 0.08
- tumor necrosis factor receptor 1 measurement · score 0.07
- breast cancer · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Experimental structures are not indexed in MolForge yet —
search RCSB PDB for Q9UKF6.
Amino-acid sequence (684 residues)
MSAIPAEESD QLLIRPLGAG QEVGRSCIIL EFKGRKIMLD CGIHPGLEGM DALPYIDLID PAEIDLLLIS HFHLDHCGAL PWFLQKTSFK GRTFMTHATK AIYRWLLSDY VKVSNISADD MLYTETDLEE SMDKIETINF HEVKEVAGIK FWCYHAGHVL GAAMFMIEIA GVKLLYTGDF SRQEDRHLMA AEIPNIKPDI LIIESTYGTH IHEKREEREA RFCNTVHDIV NRGGRGLIPV FALGRAQELL LILDEYWQNH PELHDIPIYY ASSLAKKCMA VYQTYVNAMN DKIRKQININ NPFVFKHISN LKSMDHFDDI GPSVVMASPG MMQSGLSREL FESWCTDKRN GVIIAGYCVE GTLAKHIMSE PEEITTMSGQ KLPLKMSVDY ISFSAHTDYQ QTSEFIRALK PPHVILVHGE QNEMARLKAA LIREYEDNDE VHIEVHNPRN TEAVTLNFRG EKLAKVMGFL ADKKPEQGQR VSGILVKRNF NYHILSPCDL SNYTDLAMST VKQTQAIPYT GPFNLLCYQL QKLTGDVEEL EIQEKPALKV FKNITVIQEP GMVVLEWLAN PSNDMYADTV TTVILEVQSN PKIRKGAVQK VSKKLEMHVY SKRLEIMLQD IFGEDCVSVK DDSILSVTVD GKTANLNLET RTVECEEGSE DDESLREMVE LAAQRLYEAL TPVH
Explore Cleavage and polyadenylation specificity factor subunit 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets